Anlotinib suppresses lung adenocarcinoma growth via inhibiting FASN-mediated lipid metabolism

BACKGROUND: Anlotinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, has been widely used in advanced lung cancer patients, but the intrinsic mechanism of cancer cell elimination is not fully disclosed. In this study, we reported that anlotinib suppressed lung adenocarcinoma (LUAD...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Juan, Huang, Jie, Huang, Yu, Chen, Yidan, Li, Jiawei, Luo, Peihua, Zhang, Qianyun, Qiu, Yao, Wang, Lie, Jiang, Hong, Ma, Shenglin, Chen, Xueqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843377/
https://www.ncbi.nlm.nih.gov/pubmed/36660682
http://dx.doi.org/10.21037/atm-22-5438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843377/
https://www.ncbi.nlm.nih.gov/pubmed/36660682
http://dx.doi.org/10.21037/atm-22-5438

Ejemplares similares